International Biotechnology Trust Plc Buys ChemoCentryx Inc, PTC Therapeutics Inc, Zogenix Inc, Sells Regeneron Pharmaceuticals Inc, Stemline Therapeutics Inc, Illumina Inc

• New Purchases: CCXI, LLY, ENTA, PRNB, IMMU, ALKS, ALLK, ITCI,
• Added Positions: PTCT, ZGNX, BMRN, INCY, QURE, MRTX, HZNP,
• Reduced Positions: GILD, VRTX, NBIX, ALNY, XLRN, NKTR, SRPT, AMRN, ALXN, ESPR, GBT, MNTA, MYOK, KALV, SGEN, AGIO, BLUE, BPMC, TCDA, SAGE,
• Sold Out: REGN, STML, ILMN, NVCR, SGMO, BGNE, GMED, IFRX, MYGN, AKCA, SUPN, DERM, MOR, RDUS, GTHX,

For the details of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's stock buys and sells, go to https://www.gurufocus.com/guru/international+biotechnology+trust+plc/current-portfolio/portfolio

1. Vertex Pharmaceuticals Inc (VRTX) - 77,822 shares, 8.44% of the total portfolio. Shares reduced by 16.7%
2. Gilead Sciences Inc (GILD) - 237,284 shares, 8.08% of the total portfolio. Shares reduced by 19.09%
3. Biogen Inc (BIIB) - 45,700 shares, 6.59% of the total portfolio.
4. Biomarin Pharmaceutical Inc (BMRN) - 169,784 shares, 6.54% of the total portfolio. Shares added by 62.81%
5. ACADIA Pharmaceuticals Inc (ACAD) - 337,000 shares, 6.49% of the total portfolio. Shares added by 0.30%

International Biotechnology Trust Plc initiated holding in ChemoCentryx Inc. The purchase prices were between $32.73 and $50.78, with an estimated average price of $42.52. The stock is now traded at around $53.80. The impact to a portfolio due to this purchase was 3.48%. The holding were 190,000 shares as of .

International Biotechnology Trust Plc initiated holding in Eli Lilly and Co. The purchase prices were between $119.05 and $147.35, with an estimated average price of $137.4. The stock is now traded at around $159.23. The impact to a portfolio due to this purchase was 1.26%. The holding were 20,000 shares as of .

International Biotechnology Trust Plc initiated holding in Enanta Pharmaceuticals Inc. The purchase prices were between $40.22 and $62, with an estimated average price of $53.48. The stock is now traded at around $55.20. The impact to a portfolio due to this purchase was 1.09%. The holding were 46,500 shares as of .

International Biotechnology Trust Plc initiated holding in Principia Biopharma Inc. The purchase prices were between $43.5 and $74.09, with an estimated average price of $58.41. The stock is now traded at around $64.11. The impact to a portfolio due to this purchase was 0.62%. The holding were 23,100 shares as of .

International Biotechnology Trust Plc initiated holding in Immunomedics Inc. The purchase prices were between $9.48 and $21.16, with an estimated average price of $16.95. The stock is now traded at around $33.96. The impact to a portfolio due to this purchase was 0.44%. The holding were 72,000 shares as of .

International Biotechnology Trust Plc initiated holding in Alkermes PLC. The purchase prices were between $13.06 and $21.24, with an estimated average price of $17.91. The stock is now traded at around $15.27. The impact to a portfolio due to this purchase was 0.34%. The holding were 52,000 shares as of .

International Biotechnology Trust Plc added to a holding in PTC Therapeutics Inc by 135.96%. The purchase prices were between $32.37 and $59.36, with an estimated average price of $50.48. The stock is now traded at around $48.83. The impact to a portfolio due to this purchase was 3.15%. The holding were 269,000 shares as of .

International Biotechnology Trust Plc added to a holding in Zogenix Inc by 559.95%. The purchase prices were between $17.8 and $56.59, with an estimated average price of $36.87. The stock is now traded at around $27.60. The impact to a portfolio due to this purchase was 2.69%. The holding were 281,797 shares as of .

International Biotechnology Trust Plc added to a holding in Biomarin Pharmaceutical Inc by 62.81%. The purchase prices were between $71.37 and $96.85, with an estimated average price of $86.22. The stock is now traded at around $93.74. The impact to a portfolio due to this purchase was 2.52%. The holding were 169,784 shares as of .

International Biotechnology Trust Plc added to a holding in Incyte Corp by 55.47%. The purchase prices were between $63.18 and $87.32, with an estimated average price of $75.84. The stock is now traded at around $96.12. The impact to a portfolio due to this purchase was 1.18%. The holding were 99,500 shares as of .

International Biotechnology Trust Plc added to a holding in uniQure NV by 103.70%. The purchase prices were between $40.01 and $73.97, with an estimated average price of $57.92. The stock is now traded at around $58.33. The impact to a portfolio due to this purchase was 0.3%. The holding were 27,500 shares as of .

International Biotechnology Trust Plc added to a holding in Mirati Therapeutics Inc by 22.28%. The purchase prices were between $69.78 and $128.86, with an estimated average price of $90.44. The stock is now traded at around $103.37. The impact to a portfolio due to this purchase was 0.28%. The holding were 43,900 shares as of .

International Biotechnology Trust Plc sold out a holding in Regeneron Pharmaceuticals Inc. The sale prices were between $336.18 and $494.43, with an estimated average price of $411.31.

International Biotechnology Trust Plc sold out a holding in Stemline Therapeutics Inc. The sale prices were between $3.41 and $10.79, with an estimated average price of $6.56.

International Biotechnology Trust Plc sold out a holding in Illumina Inc. The sale prices were between $209.2 and $335.53, with an estimated average price of $288.89.

International Biotechnology Trust Plc sold out a holding in NovoCure Ltd. The sale prices were between $57.05 and $95.75, with an estimated average price of $79.54.

International Biotechnology Trust Plc sold out a holding in Sangamo Therapeutics Inc. The sale prices were between $5.05 and $8.85, with an estimated average price of $7.45.

International Biotechnology Trust Plc sold out a holding in BeiGene Ltd. The sale prices were between $121.84 and $173.19, with an estimated average price of $156.97.

International Biotechnology Trust Plc reduced to a holding in Alnylam Pharmaceuticals Inc by 48.5%. The sale prices were between $93.12 and $133.99, with an estimated average price of $115.68. The stock is now traded at around $139.28. The impact to a portfolio due to this sale was -0.87%. International Biotechnology Trust Plc still held 22,300 shares as of .

International Biotechnology Trust Plc reduced to a holding in Acceleron Pharma Inc by 68.42%. The sale prices were between $50.95 and $95.31, with an estimated average price of $77.26. The stock is now traded at around $102.11. The impact to a portfolio due to this sale was -0.75%. International Biotechnology Trust Plc still held 18,000 shares as of .

International Biotechnology Trust Plc reduced to a holding in Nektar Therapeutics by 52.14%. The sale prices were between $14.47 and $27.96, with an estimated average price of $20.7. The stock is now traded at around $22.02. The impact to a portfolio due to this sale was -0.57%. International Biotechnology Trust Plc still held 67,000 shares as of .

International Biotechnology Trust Plc reduced to a holding in Sarepta Therapeutics Inc by 29.93%. The sale prices were between $82.38 and $131.64, with an estimated average price of $114.91. The stock is now traded at around $141.25. The impact to a portfolio due to this sale was -0.56%. International Biotechnology Trust Plc still held 28,100 shares as of .